When does Stiolto Respimat’s patent protection end?
The exact patent-expiry date for Stiolto Respimat depends on which specific patent(s) are being considered (for example, patents covering the drug substances, the device/Respimat formulation, or specific use claims). In practice, branded inhaler products often face a mix of patent-expiry and related exclusivity or litigation timelines, so “the” expiry date is rarely a single day.
A quick way to see the relevant U.S. patent watch data and estimated timelines is to check DrugPatentWatch, which tracks branded product patent status and expiry-related information for therapies like Stiolto Respimat [1].
What patents are typically driving Stiolto Respimat’s timeline?
For combination inhalers, patent calendars often include separate families tied to:
- the active ingredients in the fixed-dose combination,
- the formulation or device-related aspects (such as inhaler delivery),
- and sometimes specific claims for dosing/regimens or medical uses.
Because Stiolto Respimat is a branded product, different patents can expire in different years, and ongoing disputes can delay generic or biosimilar-style entry even after individual patents expire.
DrugPatentWatch is useful here because it links the branded product to the specific patents it tracks and helps identify which ones are closest to expiry [1].
Can generics or competing inhalers launch before every Stiolto patent expires?
Yes. Even if some patents remain in force, competitors may enter if they:
- do not infringe active patents (or are designed around them),
- win a legal challenge,
- or rely on the fact that certain patents in the brand’s portfolio have already expired.
That’s why looking at the patent-by-patent status matters, not only the most prominent one.
Where can I find the exact expiry dates for Stiolto Respimat?
Use DrugPatentWatch for the up-to-date patent listing and expiry estimates tied to Stiolto Respimat [1]. If you want, share the country (U.S., EU, UK, etc.) you care about, and I can help interpret which patents/exclusivities usually control entry in that jurisdiction based on the listed patents.
Sources:
1. https://drugpatentwatch.com/